DaVita Inc. (NYSE: DVA) reported improved performance in its participation in the Comprehensive Kidney Care Contracting program, a federal value-based care demonstration managed by the Center for Medicare & Medicaid Innovation.

The Denver-based kidney care provider achieved a 9% improvement in its Total Quality Score for 2024, driven by gains in treatment starts, patient activation and behavioral health support. DaVita entities have delivered more than $200 million in shared savings since the program began.

The company and its physician partners accounted for 34% of the program's High Performers Pool while representing 28% of participants, according to performance results published by the Centers for Medicare & Medicaid Services.

The CKCC program enables providers to test coordinated care approaches for kidney disease patients. Performance data shows patients with access to the program are more likely to begin kidney replacement therapy with planned starts, experience lower rates of central venous catheter use, and have fewer missed treatments.

"People living with kidney disease often manage multiple chronic conditions, and strong outcomes depend on close collaboration across the care team," said Dr. Jeff Giullian, chief medical officer for DaVita.

DaVita manages more than $5 billion in medical costs under management across its value-based care arrangements. The company operates 3,242 outpatient dialysis centers as of December 31, 2025, serving approximately 295,000 patients worldwide.

The company has participated in value-based care arrangements for more than two decades. Misha Palecek, chief transformation officer, said the results demonstrate early signs of financial sustainability alongside improved patient outcomes.